Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation

Experimental Cell Research

Volumn 288, Issue 2, 2003, Pages 257-267

  Ariztia, E V ^a   Subbarao, V ^a   Solt, D B ^a   Rademaker, A W ^a   Iyer, A P ^a   Oltvai, Z N ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hepatocyte growth factor; Invasiveness; Metastasis; Osteopontin; Tumor growth

Indexed keywords

OSTEOPONTIN; PROTEIN KINASE; SCATTER FACTOR;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL CULTURE; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; GENE EXPRESSION; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCREENING TEST; TUMOR GROWTH;

EID: 0042063658     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(03)00118-6     Document Type: Article

References (48)

1. Jeffers M., Rong S., Woude G.F.Vande. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J. Mol. Med. 74:1996;505-513.
2. Trusolino L., Pugliese L., Comoglio P.M. Interactions between scatter factors and their receptors hints for therapeutic applications . FASEB J. 12:1998;1267-1280.
3. Chirgadze D.Y., Hepple J., Byrd R.A., Sowdhamini R., Blundell T.L., Gherardi E. Insights into the structure of hepatocyte growth factor/scatter factor (HGF/SF) and implications for receptor activation. FEBS Lett. 430:1998;126-129.
4. Birchmeier C., Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8:1998;404-410.
5. To C.T., Tsao M.S. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers. Oncol. Rep. 5:1998;1013-1024.
6. Nakamura T., Matsumoto K., Kiritoshi A., Tano Y., Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells in vitro analysis of tumor-stromal interactions . Cancer Res. 57:1997;3305-3313.
7. Nakashiro K., Okamoto M., Hayashi Y., Oyasu R. Hepatocyte growth factor secreted by prostate-derived stromal cells stimulates growth of androgen-independent human prostatic carcinoma cells. Am. J. Pathol. 157:2000;795-803.
8. Boccaccio C., Ando M., Tamagnone L., Bardelli A., Michieli P., Battistini C., Comoglio P.M. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 391:1998;285-288.
9. Bardelli A., Longati P., Gramaglia D., Basilico C., Tamagnone L., Giordano S., Ballinari D., Michieli P., Comoglio P.M. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc. Natl. Acad. Sci. USA. 95:1998;14379-14383.
10. Ponzetto C., Bardelli A., Maina F., Longati P., Panayotou G., Dhand R., Waterfield M.D., Comoglio P. A novel recognition motif for phosphatidylinositol 3-kinase binding motif mediates its association with the hepatocyte growth factor/scatter factor receptor. Mol. Cell. Biol. 13:1993;4600-4608.
11. Ponzetto C., Bardelli A., Zhen Z., Maina F., dalla Zonca P., Giordano S., Graziani A., Panayotou G., Comoglio P.M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 77:1994;261-271.
12. Weidner K.M., Cesare S.D.i, Sachs M., Brinkmann V., Behrens J., Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature. 384:1996;173-176.
13. Ponzetto C., Zhen Z., Audero E., Maina F., Bardelli A., Basile M.L., Giordano S., Narsimhan R., Comoglio P. Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility. J. Biol. Chem. 271:1996;14119-14123.
14. Giordano S., Bardelli A., Zhen Z., Menard S., Ponzetto C., Comoglio P.M. A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc. Natl. Acad. Sci. USA. 94:1997;13868-13872.
15. Johnson M., Koukoulis G., Matsumoto K., Nakamura T., Iyer A. Hepatocyte growth factor induces proliferation and morphogenesis in nonparenchymal epithelial liver cells. Hepatology. 17:1993;1052-1061.
16. St John T.P., Davis R.W. Isolation of galactose-inducible DNA sequences from Saccharomyces cerevisiae by differential plaque filter hybrzvolion. Cell. 16:1979;443-452.
17. Rittling S.R., Feng F. Detection of mouse osteopontin by western blotting. Biochem. Biophys. Res. Commun. 250:1998;287-292.
18. Kanda H., Tajima H., Lee G.H., Nomura K., Ohtake K., Matsumoto K., Nakamura T., Kitagawa T. Hepatocyte growth factor transforms immortalized mouse liver epithelial cells. Oncogene. 8:1993;3047-3053.
19. Albini A., Iwamoto Y., Kleinman H.K., Martin G.R., Aaronson S.A., Kozlowski J.M., McEwan R.N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47:1987;3239-3245.
20. Behrend E.I., Craig A.M., Wilson S.M., Denhardt D.T., Chambers A.F. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 54:1994;832-837.
21. Gardner H.A., Berse B., Senger D.R. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasta. Oncogen. 9:1994;2321-2326.
22. Su L., Mukherjee A.B., Mukherjee B.B. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogen. 10:1995;2163-2169.
23. Crawford H.C., Matrisian L.M., Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 58:1998;5206-5215.
24. Hu D.D., Hoyer J.R., Smith J.W. Characterization of the interaction between integrins and recombinant human osteopontin. Ann. N. Y. Acad. Sci. 760:1995;312-314.
25. Tuck A.B., Arsenault D.M., O'Malley F.P., Hota C., Ling M.C., Wilson S.M., Chambers A.F. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene. 18:1999;4237-4246.
26. Adachi T., Nakashima S., Saji S., Nakamura T., Nozawa Y. Phospholipase D activation in hepatocyte growth factor-stimulated rat hepatocytes mediates the expressions of c-jun and c-fos involvement of protein tyrosine kinase, protein kinase C, and Ca2+ . Hepatology. 24:1996;1274-1281.
27. Gomez-Lechon M.J., Guillen I., Ponsoda X., Fabra R., Trullenque R., Nakamura T., Castell J.V. Cell cycle progression proteins (cyclins), oncogene expression, and signal transduction during the proliferative response of human hepatocytes to hepatocyte growth factor. Hepatology. 23:1996;1012-1019.
28. Desiderio M.A., Pogliaghi G., Dansi P. Hepatocyte growth factor-induced expression of ornithine decarboxylase, c-met, and c-myc is differently affected by protein kinase inhibitors in human hepatoma cells HepG2. Exp. Cell Res. 242:1998;401-409.
29. Rosen E.M., Goldberg I.D., Liu D., Setter E., Donovan M.A., Bhargava M., Reiss M., Kacinski B.M. Tumor necrosis factor stimulates epithelial tumor cell motility. Cancer Res. 51:1991;5315-5321.
30. Hotta H., Ross A.H., Huebner K., Isobe M., Wendeborn S., Chao M.V., Ricciardi R.P., Tsujimoto Y., Croce C.M., Koprowski H. Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res. 48:1988;2955-2962.
31. Wright M.D., Tomlinson M.G. The ins and outs of the transmembrane 4 superfamily. Immunol. Today. 15:1994;588-594.
32. Maecker H.T., Todd S.C., Levy S. The tetraspanin superfamily molecular facilitators . FASEB J. 11:1997;428-442.
33. Hemler M.E. Integrin associated proteins. Curr. Opin. Cell Biol. 10:1998;578-585.
34. Oates A.J., Barraclough R., Rudland P.S. The role of osteopontin in tumorigenesis and metastasis. Invasion & Metastasis. 17:1997;1-15.
35. Katagiri Y.U., Sleeman J., Fujii H., Herrlich P., Hotta H., Tanaka K., Chikuma S., Yagita H., Okumura K., Murakami M., Saiki I., Chambers A.F., Uede T. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine- glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 59:1999;219-226.
36. Chambers A.F., Wilson S.M., Kerkvliet N., O'Malley F.P., Harris J.F., Casson A.G. Osteopontin expression in lung cancer. Lung Cancer. 15:1996;311-323.
37. Craig A.M., Nemir M., Mukherjee B.B., Chambers A.F., Denhardt D.T. Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem. Biophys. Res. Commun. 157:1988;166-173.
38. Singhal H., Bautista D.S., Tonkin K.S., O'Malley F.P., Tuck A.B., Chambers A.F., Harris J.F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res. 3:1997;605-611.
39. Tuck A.B., O'Malley F.P., Singhal H., Tonkin K.S., Harris J.F., Bautista D., Chambers A.F. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med. 121:1997;578-584.
40. Sung V., Gilles C., Murray A., Clarke R., Aaron A.D., Azumi N., Thompson E.W. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. Exp. Cell Res. 241:1998;273-284.
41. Medico E., Gentile A., Lo Celso C., Williams T.A., Gambarotta G., Trusolino L., Comoglio P.M. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res. 61:2001;5861-5868.
42. Tuck A.B., Elliott B.E., Hota C., Tremblay E., Chambers A.F. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J. Cell. Biochem. 78:2000;465-475.
43. Smith L.L., Cheung H.K., Ling L.E., Chen J., Sheppard D., Pytela R., Giachelli C.M. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J. Biol. Chem. 271:1996;28485-28491.
44. Weber G.F., Ashkar S., Glimcher M.J., Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 271:1996;509-512.
45. Varner J.A., Cheresh D.A. Integrins and cancer. Curr. Opin. Cell Biol. 8:1996;724-730.
46. Naot D., Sionov R.V., Ish-Shalom D. CD44 structure, function, and association with the malignant process . Adv. Cancer Res. 71:1997;241-319.
47. van der Voort R., Taher T.E., Wielenga V.J., Spaargaren M., Prevo R., Smit L., David G., Hartmann G., Gherardi E., Pals S.T. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J. Biol. Chem. 274:1999;6499-6506.
48. Ashkar S., Weber G.F., Panoutsakopoulou V., Sanchirico M.E., Jansson M., Zawaideh S., Rittling S.R., Denhardt D.T., Glimcher M.J., Cantor H. Eta-1 (Osteopontin) an early component of type-1 (Cell-mediated) immunity . Science. 287:2000;860-864.